|Subsidiary (formerly: Public)|
|Traded as||Formerly NASDAQ: CBST|
|Industry||Pharmaceuticals (Biopharmaceuticals & Biotherapeutics)|
|Robert J. Perez, President, CEO;|
|Revenue||$926.4 million USD (2012)|
|Parent||Merck & Co.|
Cubist Pharmaceuticals was a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA.
Cubist was one of the few firms that continued to research in antibiotics while larger pharmaceutical companies have abandoned such research. The company employs 638 people, with 370 in their headquarters in Lexington, MA. As of 2011, the company’s headquarters are under expansion and is expected to occupy 373,000 sq ft (34,700 m2) in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion) as entree to the market for drugs that can combat superbugs.
Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry Bloom, Ph.D, all of whom were also directors. Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500. In 2006 it had the 19th highest sales among American based biotechnology companies.
Cubist had an ambitious growth plan laid out for the 2012-2017 quinquennium. Under this plan, the company was expected to reach 2B dollars in sales and have 4 new drugs in late stage development by 2017. As a part of this plan, sales of its flagship drug Cubicin were expected to grow to more than 1B dollars per year.
In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015. In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.
The company markets Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin. In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year). Optimer chose Cubist because according to its CEO, "Cubist has a proven track record and well established relations with all stakeholders involved in the antibiotics space".
- Mullin, Emily (26 Aug 2014). "Cubist exec: Challenges mount in antibiotics discovery". Fiercebiotechresearch.com. Retrieved 23 Nov 2014.
- "Cubist Pharmaceuticals Inc. homesite". 2009 Annual Report. Retrieved 20 May 2011.
- Merck to take on superbugs with Cubist Pharma buy. Reuters, 9 December 2014
- "SEC Form S3 Cubist Pharmaceuticals, Inc". March 8, 2000.
- "100 FASTEST-GROWING COMPANIES". CNN. 2010. Retrieved 28 May 2011.
- Associated Press (19 Jan 2012), "Cubist Profit Down 53%", Drug Discovery & Development, Advantage Business Media, retrieved 22 Jan 2012
- Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
- Weisman, Robert (20 Oct 2014). "New Cubist Pharmaceuticals chief executive will be Robert J. Perez". www.BostonGlobe.com. Retrieved 23 Nov 2014.
- "Cubist Settles Teva Patent Litigation on Antibiotic Cubicin". Bloomberg. 2011-04-05. Retrieved 28 May 2011.
- "Optimer to Market Dificid Drug With Cubist Pharmaceuticals". Bloomberg. 2011-04-06.
- Donnelly, Julie M. (13 December 2011). "Cubist advances antibiotic for Gram-negative bacteria". www.bizjournals.com. Retrieved 2017-10-31.
- Brown, Rodney H. (6 April 2011). "Cubist - Optimer diarrhea drug could net $47M". www.bizjournals.com. Retrieved 2017-10-31.
- "Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs". GenomeWeb. Retrieved 2017-10-31.
- "Sivextro by Cubist Pharmaceuticals". www.pharmacytimes.com. Retrieved 2017-10-31.
- "Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review | FierceBiotech". www.fiercebiotech.com. Retrieved 2017-10-31.
- Kennedy, Val Brickates, "Nothing bugs Cubist CEO Michael Bonney", MarketWatch, January 17, 2012.